Adjuvant transcranial direct current stimulation for treating Alzheimer’s disease

A case study

Suellen Marinho Andrade¹, Camila Teresa Ponce Leon de Mendonça¹, Thobias Cavalcanti Laurindo Pereira¹, Bernardino Fernandez-Calvo¹, Regina Coely Neves Araújo¹, Nelson Torro Alves¹

ABSTRACT. We report the case of a 73-year-old male patient with Alzheimer’s disease who underwent 10-daily transcranial direct current stimulation (tDCS) sessions. tDCS was applied over the left dorsolateral prefrontal cortex as an adjuvant to the traditional treatment that the patient was receiving, which consisted of anticholinergic medication and cognitive training. The data were qualitatively analyzed and are presented in an analytic and structured form. The effects on cognitive performance were evaluated using the Alzheimer’s Disease Assessment Scale-cognitive subscale as the primary outcome. Secondary outcomes were assessed with a set of tests consisting of the Neuropsychiatric Inventory, the Blessed Dementia Scale and the Disability Assessment for Dementia. The data obtained revealed that the application of tDCS had a stabilizing effect on overall patient cognitive function and led to improved performance on all the secondary outcome tests. These preliminary results indicate that tDCS is a potential adjuvant therapeutic tool for cognitive rehabilitation in Alzheimer’s disease.

Key words: electrical stimulation, dementia, Alzheimer’s disease, cognitive therapy.

INTRODUCTION

Alzheimer’s disease (AD) is the most common form of dementia in the elderly population and is characterized by cognitive and behavioral changes that interfere with social relationships and functional activities.¹ Non-pharmacological strategies have been used to delay these cognitive deficits and minimize functional impairment. One of these strategies is transcranial direct current stimulation (tDCS), a low-cost, portable, safe method that is capable of modulating corti-
cal activity and inducing neuroplasticity mechanisms.¹² However, there is a dearth of studies evaluating cognitive and behavioral measures following treatment for AD with tDCS, especially when combined with other traditional treatments, such as anticholinergic medication or cognitive therapy.¹³

This case report provides evidence of the efficacy of tDCS as an adjuvant therapy in the treatment of patients with Alzheimer’s; this therapy was associated with improved performance on cognitive and behavioral tests.

**METHODS**

**Case history.** A 73-year-old male patient with higher education was referred to our research center by the National Alzheimer’s Association. Two years prior, the patient had been diagnosed with AD according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA). The patient had mild cognitive impairment and a score of 1 on the Clinical Dementia Rating scale.¹⁴

The patient’s family reported several AD symptoms, including difficulty remembering recent events, language impairment, spatiotemporal disorientation and decreased decision-making capacity; these symptoms interfered with his independence in activities of daily living (ADL).

The patient was receiving treatment with donepezil (10 mg/day for 12 months) and sertraline (50 mg/day for 6 months) for symptoms of depression that had arisen after the AD diagnosis and were currently in remission (a score of 6 according to the Cornell Scale for Depression in Dementia). In addition to medication, the patient was undergoing cognitive training sessions with a neuropsychologist twice per week. These sessions involved tasks related to memory, language, attention, executive functions and praxis.

The local Ethics Committee approved the study protocol (44388015.7.0000.5188), and the patient signed an informed consent form agreeing to participate in the study. Medication use and cognitive therapy sessions continued throughout the study, with tDCS used as an adjuvant treatment for AD.

**Measures.** Assessments were performed at two different time points, one week prior to (T0), and one week after (T1), the neurostimulation protocol. The ADAS-Cog was used for the primary outcome assessment. This scale includes items related to memory, language, praxis and orientation. To measure secondary outcomes, the following instruments were applied: the Neuropsychiatric Inventory (NPI),¹⁵ for the evaluation of non-cognitive AD symptoms, such as delusions, hallucinations, euphoria and apathy; the Blessed Dementia Scale,¹⁶ which assesses ADL, changes in habits and behavior disorders; and the Disability Assessment for Dementia (DAD),¹⁷ which quantitatively measures functional abilities in ADL and cognitive dimensions of impairments in ADL in relation to executive functions.

A questionnaire on adverse effects was administered to assess the safety of the method. The patient was asked at each stimulation session whether he experienced any discomfort, which was graded on a Likert scale from 0 to 5 points for intensity of the experience.⁸

**tDCS.** tDCS was applied with a 2 mA current for 30 minutes on 10 consecutive days (excluding weekends). The TCT neurostimulator (Research version; Trans Cranial Technologies) was used, with 5 x 7 cm (35 cm²) electrodes wrapped in sponges moistened with saline (NaCl 0.9%). The anode was placed over the dorsolateral prefrontal cortex (region F3 according to the international 10-20 electroencephalography [EEG] system).⁹ The reference electrode was placed over the supraorbital region.

**RESULTS**

The data were qualitatively analyzed and are presented in an analytic and structured form. Table 1 shows the changes in scores and percentage improvement with treatment.¹⁰ At baseline, the patient had significant deficits in recalling words (ADAS-Cog subscale) and in execution efficacy (DAD subscale). For the tests applied, negative values indicate an improvement after treatment (T1) because higher scores on these scales denote more severe cognitive impairment. Specifically, the patient’s improvement was greater on the domains that were most affected at baseline, i.e., those related to verbal memory and executive functions. Clinically, the patient’s family reported improvements in decision-making and ADL. Regarding adverse events, the therapy was well tolerated; the only discomfort reported was temporary itching during the initial minutes of neurostimulation.

**DISCUSSION**

It is well established in the literature that anticholinergic medication and cognitive therapy can provide AD patients with some benefits.¹¹,¹² The present study has expanded research on AD treatments by showing that tDCS is capable of producing cognitive and behavioral changes. We observed that this method was safe and had minimal adverse effects.
Table 1. Cognitive performances of patient before and after tDCS application

| Neuropsychological tests       | T0 | T1 | Change scores* | %improvement** |
|-------------------------------|----|----|----------------|----------------|
| **ADAS-Cog**                  |    |    |                |                |
| Word Recall Test              | 6  | 5  | −1*            | 16.0           |
| Naming objects and Fingers    | 0  | 0  | 0              | 0              |
| Commands                      | 1  | 0  | −1*            | 100            |
| Constructional Praxis         | 1  | 1  | 0              | 0              |
| Ideational Praxis             | 2  | 2  | 0              | 0              |
| Orientation                   | 2  | 1  | −1*            | 50.0           |
| Word Recognition Task         | 2  | 2  | 0              | 0              |
| Remembering Test Instructions | 1  | 1  | 0              | 0              |
| Spoken Language Ability       | 1  | 0  | −1*            | 100            |
| Word Finding Difficulty       | 0  | 0  | 0              | 0              |
| Comprehension                 | 0  | 0  | 0              | 0              |
| **Total**                     | 16 | 12 | −4*            | 25.0           |
| **NPI-Q**                     |    |    |                |                |
|                               | 42 | 14 | −28*           | 66.6           |
| **BDS**                       |    |    |                |                |
|                               | 7  | 4.5| −2.5*          | 35.7           |

ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive Subscale; NPI-Q: Neuropsychiatric Inventory Questionnaire; BDS: Blessed Dementia Scale; DAD: Disability Assessment for Dementia. *Change scores [difference between post (T1) and pre-intervention (T0)]. **Percentages improvement from baseline were calculated with the equation: [(T1–T0)/T0] x 100. Negative values on the ADAS-Cog, NPI-Q and BDS categories in Table 1 indicate improvement.

The patient in our case study presented a relevant decrease in ADAS-Cog scores equivalent to the improvement achieved by patients who undergo several months of traditional treatment. A systematic review of studies evaluating the effects of medication on AD found that during the initial 6-12 months, patients treated with cholinesterase inhibitors had an average improvement of 2.7 points. However, a study of 784 patients treated with donepezil, rivastigmine or galantamine found that 49% of patients had improved or unchanged ADL and that 51% experienced a decrease in independent living.

In this context, our recommendation for the use of tDCS would not be to replace drug or cognitive treatment for AD patients. Instead, tDCS would function in a complimentary manner as an adjuvant, enhancing gains obtained or preventing rapid disease progression, as previously observed in studies involving neuromodulation and behavior therapy in AD patients. A double-blind, placebo-controlled, randomized trial with 15 AD patients found that transcranial magnetic stimulation, a method similar to tDCS, combined with cognitive therapy, was able to reduce the average ADAS-Cog score by 3.76 points in the treated group after 6 weeks compared to the placebo group. A recent study reported that the
effects of tDCS on a patient’s overall cognitive function persisted for up to 3 months of follow-up, supporting the use of tDCS as an adjuvant tool in AD treatment.\textsuperscript{18}

Although there is evidence of improvements in behavior and function in AD patients undergoing tDCS treatment,\textsuperscript{2,19} the mechanisms underlying these effects on cognitive functions are not fully understood; the effects might be related to neural plasticity and the actions of different neurotransmitters.\textsuperscript{20} tDCS has been used to increase cortical activity in AD patients because this patient group exhibits temporoparietal hypoparvocytosis.\textsuperscript{21} The literature shows that tDCS alters neural activity and blood flow in the brain, causes synaptic and non-synaptic after-effects, and can modify neuronal polarization and functional connectivity patterns in the brain.\textsuperscript{22}

In the present case, we were not able to evaluate changes in cortical or subcortical activity because our measurements were not based on neuroimaging or biomarker methods. Additional studies using these methods would be needed to clarify the relationship between the observed improvements on cognitive tests and changes at the cellular level.

Our results are in agreement with previously published studies reporting positive changes in behavior after tDCS. These findings are promising and indicate that tDCS is an option for adjuvant treatment to improve the prognosis of AD patients.

**Author contribution.** Suellen Andrade: Study conception design, drafting of manuscript and interpretation of data; Bernardino Fernández-Calvo, Nelson Torro Alves and Regina Neves: Critical revision; Camila Mendonça and Thobias Pereira: Acquisition and interpretation of data.

**Acknowledgments.** This study was partly funded by Coordination for the Improvement of Higher Education Personnel (CAPES).

**REFERENCES**

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7: 263-269.

2. Boggio OS, Ferrucci R, Mameli F, et al. Prolonged visual memory enhancement after direct current stimulation in Alzheimer’s disease. Brain Stimulat 2012;5:223-230.

3. Bottino CMC, Carvalho IAM, Alvarez AMMA, et al. Cognitive rehabilitation in Alzheimer’s disease patients: multidisciplinary team report. Arq Neuropsiquiatr 2002;60:70-79.

4. Hughes CP, Berg L, Danzinger, WL, Cohen, LA, Martin, AL. A New Clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.

5. Rosen WC, Mohs RC, Davis KL. A new rating scale for Alzheimer’s Disease. Am J Psychiatry 1984;141:1356-1364.

6. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.

7. Gauthier L, Gélinas I, McIntyre M, Gauthier S, Laberge H, Dauphinee SW. Disability Assessment for Dementia (DAD) user’s guide, 1994.

8. Brunoni AR, Valergo L, Baccaro A, et al. Sertraline vs. electrical current therapy for treating depression clinical trial-Select TDCS: design, rationale and objectives. Contemp Cln Trials 2011;32:90-98.

9. Carvalho S, Boggio P S, Gonçalves O S, et al. Transcranial direct current stimulation based metalasticity protocols in work memory. Brain Stimul 2015; 8:299-294.

10. Haffern E, Choppard G, Pretall JB, et. al. A case report of daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) as an adjunctive treatment for Alzheimer disease. Brain Stimulat 2012;5: 264-266.

11. Behl P, Lancot KL, Streiner DL, Black SE. The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer’s disease: a two-year observational study in the Sunnybrook dementia cohort. Int Psychogeriatr 2008;20:1141-1159.

12. Spector A, Thorgrimsen L, Woods RT, Royan L, Davies S, Butterworth M, Orrell M. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia. Br J Psychiatry 2003;183:248-254.

13. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.

14. Wattoo C, Wallin ÅK, Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort. BMC Neurol 2012;12:1-10.

15. Bentwich J, Dobroneyevsky E, Aichenbaum S, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer’s disease: a proof of concept study. J Neural Transm 2011;118:463-471.

16. Lee J, Choi BH, Oh E, Sohn EH, Lee AY. Treatment of Alzheimer’s Disease with Repetitive Transcranial Magnetic Stimulation Combined with Cognitive Training: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study. J Cln Neurol 2015;11:171-183.

17. Rabey JM, Dobroneyevsky E, Aichenbaum S, Goren O, Martin RO, Khajegheft M. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer’s disease: a randomized, double-blind study. J Neural Transm 2013;120:813-819.

18. Penolazzi B, Bergamashi S, Pastore M, Villani D, Sartori G, Mondini S. Transcranial direct current stimulation and cognitive training in the rehabilitation of Alzheimer disease: A case study. Neuropsychol Rehabil 2014;1:1-19.

19. Ferruci R, Mameli F, Giudì L, et al. Transcranial direct current stimulation improves recognition memory in Alzheimer disease. Neurology 2008; 71:493–498.

20. Nardone R, Höller Y, Tezzon F, et al. Neurostimulation in Alzheimer’s disease: from basic research to clinical applications. Neurof l Sci 2015; 36:689-700.

21. Fernandez A, Maestu F, Ampuero, et al. Focal temporoparietal slow activity in Alzheimer’s disease revealed by magnetoencephalography. Biol Psychiatry 2002;52:764-770.

22. Hanssen N. Action mechanisms of transcranial direct current stimulation in Alzheimer’s disease and memory loss. Front. Psychiatry 2012;48:1-8.